Mustard gas: From deadly weapon to chemotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

By the end of World War I, the use of chemical weapons had resulted in over one million casualties on both sides, including many disabled and wounded. Through a series of unintended events, these chemical weapons set in motion discoveries that led to the development of chemotherapy.

Following the war, medical researchers noticed that mustard gas destroyed lymphatic tissue and bone marrow, leading them to experiment with applying nitrogen mustard, a derivative of mustard gas, to shrink tumors in mice. 

By the beginning of World War II in the early 1940s, the first therapeutic experiments with the intravenous use of mustard agents were conducted in patients with cancer, providing temporary benefit. Several drugs derived from mustard agents are still used today to treat certain forms of cancer.

Matthew Naylor, PhD, president and CEO of the National WWI Museum and Memorial in Kansas City, MO, described these discoveries and their impact on modern cancer treatment during the opening keynote at the 2022 AACI/CCAF Annual Meeting. 

A video of the presentation appears on the Cancer History Project.  


Johns Hopkins Kimmel Cancer Center explores the history of medical physics in a podcast 

In this podcast celebrating the 50th Anniversary of the Johns Hopkins Kimmel Cancer Center, Akila Viswanathan, director of Radiation Oncology at Johns Hopkins, speaks to John Wong, professor emeritus and former director of medical physics, about the 20th Anniversary of the Department of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins and the significant scientific achievements he has overseen throughout his tenure.


This column features the latest posts to the Cancer History Project by our growing list of contributors

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available.  

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj, or follow our podcast.

Is your institution a contributor to the Cancer History Project? Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. 

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Table of Contents

YOU MAY BE INTERESTED IN

Nan ZhangNoam AuslanderNan Zhang and Noam Auslander, the Wistar Institute assistant professors, have both received independent funding totaling $1.2 million over the next three years for cancer research projects from the V Foundation for Cancer Research. The grants are awarded to cancer researchers deemed “V Scholars” and allow Zhang and Auslander to pursue separate projects aimed at new strategies to improve the effectiveness of certain cancer therapies.
Agendia Inc. announced it will be presenting new data from the Real-World Data Registry, FLEX, demonstrating MammaPrint’s ability to predict chemotherapy benefit in patients with HR+HER2- early-stage breast cancer. The findings will be presented at the San Antonio Breast Cancer Symposium 2024. The MammaPrint test analyzes the 70 most important genes associated with breast cancer recurrence.
Timothy S. Fenske, Medical College of Wisconsin, presented findings from the ECOG-ACRIN phase III study EA4151, investigating rituximab with or without stem cell transplant in patients With minimal residual disease-negative mantle cell lymphoma in first complete remission, at the 66th ASH Annual Meeting and Exposition in San Diego. 
Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login